Bertuccio Francesco Rocco, D'Agnano Vito, Cordoni Simone, Tafa Mitela, Novy Cristina, Baio Nicola, Mucaj Klodjana, Bortolotto Chandra, Melloni Giulio, Bianco Andrea, Corsico Angelo Guido, Perrotta Fabio, Stella Giulia Maria
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, 27100 Pavia, Italy.
Unit of Respiratory Disease, Cardiothoracic and Vascular Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
J Clin Med. 2025 Jan 3;14(1):249. doi: 10.3390/jcm14010249.
Chronic obstructive pulmonary disease (COPD) is among the most relevant comorbidity associated with lung cancer. The advent of innovative triple treatment approaches for COPD has significantly improved patients' quality of life and outcomes. Few data are available regarding the impact of triple inhaler therapy on patients featuring COPD and lung cancer. We retrospectively evaluated the impact of triple inhale bronchodilators in a cohort of 56 patients with treated COPD who underwent lung surgery for primary cancer. Triple bronchodilation can help to relieve the symptoms of the disease and improve lung function, allowing people with lung cancer to reduce the risk of serious exacerbations and improve their quality of life. Within the limits of the study, it should be underlined that bronchodilators can effectively affect the outcome and performance status after thoracic surgery.
慢性阻塞性肺疾病(COPD)是与肺癌相关的最主要合并症之一。COPD创新三联治疗方法的出现显著改善了患者的生活质量和治疗效果。关于三联吸入疗法对患有COPD和肺癌患者的影响,现有数据较少。我们回顾性评估了三联吸入支气管扩张剂对56例接受原发性肺癌肺手术的已治疗COPD患者队列的影响。三联支气管扩张可有助于缓解疾病症状并改善肺功能,使肺癌患者降低严重病情加重的风险并提高生活质量。在本研究的局限性范围内,应强调支气管扩张剂可有效影响胸外科手术后的治疗效果和功能状态。